DEVELOPMENT OF AN ARG-GLY-ASP-BASED WOUND HEALING AGENT

我们建议进行临床安全性和有效性研究 一期开发的含精氨酸-甘氨酸-天冬氨酸创面愈合剂 格兰特。这个产品已被证明对改善 几种体内伤口愈合模型的愈合，并已被发现 无毒、无致突变、无免疫原性，标准相同。我们 因此建议在有限的人体临床试验中测试该化合物的安全性 审判。在确立了人类使用产品的安全性之后，我们 将开始进行小规模(18名患者)试验，以了解使用 本品用于治疗严重烧伤、慢性溃疡等引起的 血管功能不全和手术切开造成的伤口 皮肤癌。我们亦建议进行试验，以期 高效地扩大材料的生产规模。

We propose to carry out clinical safety and efficacy studies on the arg-gly-asp-containing wound healing agent developed under our Phase I grant. This product has been shown to be effective in the improvement of healing of several in vivo wound healing models, and has been found to be non-toxic, non-mutagenic and nonimmunogenic by the same criteria. We therefore propose to test this compound's safety in limited human clinical trials. After establishing the safety of the human use of the product, we will begin small (18 patient) trials into the effectiveness of the use of the product in the treatment of severe burns, chronic ulcers caused by vascular insufficiency, and the wounds resulting from the surgical incision of skin cancers. We also propose to carry out experiments leading to the efficient scale up of the production of the materials.